Evidence map›Paper›PMID 37121260›Full record

ArticleOpen biology2023

PK1 from

Thomas Zacharchenko, Till Dorendorf, Nicolas Locker, Evert Van Dijk, Anja Katzemich, Kay Diederichs, Belinda Bullard, Olga Mayans

Open access · goldAbstract read
In one paragraph

Article in Open biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. The varied functions of the giant muscle scaffold protein obscurin.Frontiers in cell and developmental biology · 2025
    Review
  4. Article
  5. PK1 fromOpen biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Thomas ZacharchenkoInstitute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK.ORCID 0000-0001-5621-8605
Till DorendorfDepartment of Biology, University of Konstanz, 78457 Konstanz, Germany.ORCID 0000-0002-8319-8010
Nicolas LockerFaculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Evert Van DijkBiosynth B.V., Zuidersluisweg 2, 8243 RC Lelystad, The Netherlands.
Anja KatzemichDepartment of Biology, University of York, York, UK.
Kay DiederichsDepartment of Biology, University of Konstanz, 78457 Konstanz, Germany.ORCID 0000-0001-5360-0905
Belinda BullardDepartment of Biology, University of York, York, UK.
Olga MayansInstitute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK.ORCID 0000-0001-6876-8532
University of Konstanz · DEUniversity of Liverpool · GBUniversity of York · GBUniversity of Surrey · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M00676X/1
6 · The paper itself

Abstract

Obscurins are large filamentous proteins with crucial roles in the assembly, stability and regulation of muscle. Characteristic of these proteins is a tandem of two C-terminal kinase domains, PK1 and PK2, that are separated by a long intrinsically disordered sequence. The significance of this conserved domain arrangement is unknown. Our study of PK1 from

Indexed as

DrosophilaMuscle ProteinsAnimalsDrosophila ProteinsProtein Serine-Threonine KinasesProtein Structure, TertiarySarcomeresDrosophila ProteinsMuscle ProteinsPk1 protein, DrosophilaProtein Serine-Threonine Kinasesmuscle sarcomerepseudokinaseX-ray crystallography

Identifiers

PMID37121260
PMCPMC10129394
OpenAlexW4366978398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.